Foundation Medicine, Celgene collaborate on genomics test
CAMBRIDGE, Mass.ó Personalized cancer diagnostics company Foundation Medicine Inc. and Celgene Corp. recently announced a strategic collaboration that focuses on the use of Foundation Medicine's comprehensive clinical cancer genomics test in ongoing trials of some of Celgene's current drug candidates. The test currently being developed will serve to aid in faster recruitment of target patient populations as well as to help with broad genetic characterization of enrollees, which has the potential to aid in identifying which patients might be most likely to respond to Celgene's drug candidates. The test uses next-generation sequencing to analyze clinical specimens for molecular changes in more than 200 cancer-related genes, and Foundation Medicine is in the process of translating its capability for clinical-grade analysis of tumor tissues into clinically relevant tests for pathologists and oncologists. No financial terms were disclosed.